Changes Possible For FDA’s Quality System Inspection Technique
This article was originally published in The Gray Sheet
FDA's Quality System Inspection Technique (QSIT) may be revised to give agency investigators more time to review device manufacturers' purchasing controls during facility inspections
You may also be interested in...
The pharmaceutical industry is more diverse today in terms of nationality and culture. However, there is still a lack of other types of diversity, which blocks the proactive inclusion of different perspectives. Raafi-Karim Alidina, a consultant with global diversity and inclusion consultancy Frost Included and the co-author of Building An Inclusive Organisation shares his thoughts.
Alexion is a case study in the travails faced by a biotech with a single blockbuster as it tries to maintain its scale and transform itself into a sustainable business, without blowing billions on bad M&A.
Legal experts note that J&J’s decision to end Johnson’s Baby Powder sales in the US and Canada closely followed a New Jersey federal court decision that largely denied the firm’s motions to bar testimony from plaintiff experts in multi-district talc litigation comprising around 16,000 cases.